Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This study aims to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab (the combination antibody) combined with SBRT and Lenvatinib in the perioperative treatment of patients with potentially resectable intermediate-stage hepatocellular carcinoma.. The objective is to explore potential survival benefits for this population and provide patients with more effective treatment options.
Epistemonikos ID: aebd456c0b5dc6b85725cccbaf1a387e92bfc43b
First added on: Sep 03, 2026